India’s Directorate General of Foreign Trade prohibited the drug, hydroxychloroquine, from being shipped outside of the country.
There are exceptions to the ban for companies that must fulfill existing contracts and on “humanitarian” grounds that will be considered and approved on a case-by-case basis, according to the report.
The decision comes after scientists said the drug may have the potential to combat COVID-19. The drug is also involved in a large multicountry study announced last week by the World Health Organization.
More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
